Hormones and hormone antagonists: Mechanisms of action in carcinogenesis of endometrial and breast cancer

Hormone and Metabolic Research

Volumn 33, Issue 8, 2001, Pages 451-457

  Flototto T ^a   Djahansouzi, S ^a   Glaser M ^a   Hanstein, B ^a   Niederacher, D ^a   Brumm, C ^b   Beckmann, M W ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Breast Cancer; Endometrial Cancer; Steroid Hormone Receptors

Indexed keywords

ESTROGEN; HORMONE; HORMONE ANTAGONIST; PROGESTERONE; STEROID; STEROID RECEPTOR; TRANSCRIPTION FACTOR;

APOPTOSIS; BINDING SITE; BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; ENDOMETRIUM CANCER; GENE EXPRESSION REGULATION; MALIGNANT TRANSFORMATION; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; SHORT SURVEY;

ANIMALS; BINDING SITES; BREAST NEOPLASMS; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENE EXPRESSION; HORMONE ANTAGONISTS; HORMONES; HUMANS; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; RECEPTORS, STEROID; STEROIDS; TRANSCRIPTION FACTORS;

EID: 0034827283     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-16936     Document Type: Short Survey

References (83)

1. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases
2. Apparition de cancers de la mamelle chez la souris mâle, soumise à des injections de folliculine C
3. Oestrogene use and risk: A review
4. Multistep carcinogenesis of breast cancer and tumour heterogeneity
5. Genetic errors, cell proliferation, and carcinogenesis
6. Somatic genetic changes in human breast cancer
7. Meeting highlights: International consensus panel on the treatment of primary breast cancer
8. Tamoxifen in the treatment of breast cancer
9. Population-based study tamoxifen therapy and subsequent ovarian, endometrial, and breast cancer
10. Endometrial carcinoma associated with breast carcinoma: Low incidence with tamoxifen use
11. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
12. Tamoxifen for early breast cancer: An overview of the randomised trials
13. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
14. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes
15. Association of exogenous oestrogen and endometrial carcinoma
16. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal oestrogen/progestin interventions (PEPI) trial
17. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer
18. The role of exogenous hormones in the epidemiology of breast ovarian and endometrial breast cancer
19. Hormonal treatment of postmenopausal women
20. The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women
21. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
22. Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?
23. Placing progesterone in the apoptotic pathway
24. Oestrogen receptors in the human female genital tract in normal and pathological conditions
25. Apoptosis in the human uterine endometrium during the menstrual cycle
26. Mechanisms of ovarian steroid hormones and antioestrogens in the development of carcinomas of the breast and endometrium
27. Oestrogen receptor expression in benign breast epithelium and breast cancer risk
28. Mechanisms of steroid hormone action and resistance in endometrial and breast cancer
29. Anti-oestrogenic action of raloxifene and tamoxifen: Today and tomorrow
30. The steroid and thyroid hormone receptor superfamily
31. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
32. Cloning of a novel receptor expressed in rat prostate and ovary
33. ER beta: Identification and characterization of a novel human oestrogen receptor
34. Cloning, chromosomal localization, and functional analysis of the murine oestrogen receptor beta
35. The complete primary structure of human oestrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro
36. Steroid hormone receptors: Many actors in search of a plot
37. Steroid and related receptors
38. Oestrogen regulated messenger RNAs in human breast cancer cells
39. Activation of the ovalbumine gene by the estrogen receptor involves the fos jun complex
40. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells
41. Oestrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer
42. Differential ligand activation of oestrogen receptors ERalpha and ERbeta at AP1 sites
43. Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53
44. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
45. Transcriptional cross-talk, the second mode of steroid hormone receptor action
46. Oestrogen receptor-associated proteins: Possible mediators of hormone-induced transcription
47. Nuclear receptor coactivators and corepressors
48. The SRC family of nuclear receptor coactivators
49. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
50. A1131, a steroid receptor coactivator amplified in breast and ovarian cancer
51. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2
52. TIF2, a 160kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors
53. p300 is a component of an oestrogen receptor coactivator complex
54. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
55. Specific, nongenomic actions of steroid hormones
56. Oestrogen hits the surface
57. Functional testosterone receptors in plasma membranes of T cells
58. 2+ in vascular smooth muscle cells
59. The neuroactive steroid 5 alpha-tetrahydrodeoxycorticosterone increases GABAergic postsynaptic inhibition in rat neocortical neurons in vitro
60. Endometrial cell calcium and oestrogen action
61. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor
62. A new, nongenomic oestrogen action: The rapid release of intracellular calcium
63. Acute activation of maxi-K channels (hSlo) by estradiol binding to the beta subunit
64. Oestrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by oestrogen
65. Oestrogen receptor-alpha detected on the plasma membrane of aldehydefixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked immunocytochemistry
66. Cell membrane and nuclear oestrogen receptors (ERs) originate from a single transcript: Studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells
67. Galpha(q/11) and gbeta-gamma proteins and membrane signaling of calcitriol and estradiol
68. Oestrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium
69. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents oestrogeninduced mitogenesis
70. In situ localization of progesterone receptors in normal mouse mammary glands: Absence of receptors in the connective and adipose stroma and a heterogeneous distribution in the epithelium
71. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
72. Ovarian ablation in early breast cancer - Overview of the randomised trials
73. Second cancers after adjuvant tamoxifen therapy for breast cancer
74. CD95 ligand expression in dedifferentiated breast cancer
75. Inhibition of c-erbB-2 oncogene expression by oestrogens in human breast cancer cells
76. Hormone-dependent regulation of BRCA1 in human breast cancer cells
77. CDK-independent activation of oestrogen receptor by cyclin D1
78. Molecular basis of agonism and antagonism in the oestrogen receptor
79. Tamoxifen induction of apoptosis in oestrogen receptor-negative cancers: New tricks for an old dog?
80. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration
81. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antioestrogen administration
82. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium
83. Tamoxifen activation of the oestrogen receptor/AP-1 pathway: Potential origin for the cell-specific oestrogen-like effects of antioestrogens